Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

529 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Incidence of and Risk Factors for Cataract in Anterior Uveitis.
Papaliodis GN, Rosner BA, Dreger KA, Fitzgerald TD, Artornsombudh P, Kothari S, Gangaputra SS, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Sen HN, Suhler EB, Thorne JE, Bhatt NP, Foster CS, Jabs DA, Pak CM, Ying GS, Kempen JH; Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study Research Group. Papaliodis GN, et al. Among authors: nussenblatt rb. Am J Ophthalmol. 2023 Oct;254:221-232. doi: 10.1016/j.ajo.2023.06.021. Epub 2023 Jul 5. Am J Ophthalmol. 2023. PMID: 37414328 Free PMC article.
Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuity.
Kaçmaz RO, Kempen JH, Newcomb C, Gangaputra S, Daniel E, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE, Jabs DA, Foster CS; Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study Group. Kaçmaz RO, et al. Among authors: nussenblatt rb. Am J Ophthalmol. 2008 Dec;146(6):828-36. doi: 10.1016/j.ajo.2008.06.019. Epub 2008 Aug 16. Am J Ophthalmol. 2008. PMID: 18708181 Free PMC article.
Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study.
Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group; Kempen JH, Altaweel MM, Drye LT, Holbrook JT, Jabs DA, Sugar EA, Thorne JE. Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, et al. Ophthalmology. 2015 Oct;122(10):1967-75. doi: 10.1016/j.ophtha.2015.06.042. Epub 2015 Aug 20. Ophthalmology. 2015. PMID: 26298715 Free PMC article. Clinical Trial.
Quality of Life and Risks Associated with Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, or Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment Trial and Follow-up Study.
Multicenter Uveitis Steroid Treatment (MUST) Trial Follow-up Study Research Group. Multicenter Uveitis Steroid Treatment (MUST) Trial Follow-up Study Research Group. Ophthalmology. 2015 Oct;122(10):1976-86. doi: 10.1016/j.ophtha.2015.06.043. Epub 2015 Aug 19. Ophthalmology. 2015. PMID: 26298718 Free PMC article. Clinical Trial.
Outcome of Treatment of Uveitic Macular Edema: The Multicenter Uveitis Steroid Treatment Trial 2-Year Results.
Tomkins-Netzer O, Lightman S, Drye L, Kempen J, Holland GN, Rao NA, Stawell RJ, Vitale A, Jabs DA; Multicenter Uveitis Steroid Treatment Trial Research Group. Tomkins-Netzer O, et al. Ophthalmology. 2015 Nov;122(11):2351-9. doi: 10.1016/j.ophtha.2015.07.036. Epub 2015 Sep 7. Ophthalmology. 2015. PMID: 26359188 Free PMC article. Clinical Trial.
Factors Predicting Visual Acuity Outcome in Intermediate, Posterior, and Panuveitis: The Multicenter Uveitis Steroid Treatment (MUST) Trial.
Kempen JH, Van Natta ML, Altaweel MM, Dunn JP, Jabs DA, Lightman SL, Thorne JE, Holbrook JT; Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group. Kempen JH, et al. Am J Ophthalmol. 2015 Dec;160(6):1133-1141.e9. doi: 10.1016/j.ajo.2015.09.017. Epub 2015 Sep 18. Am J Ophthalmol. 2015. PMID: 26386159 Free PMC article. Clinical Trial.
Long-term visual acuity outcomes following cataract surgery in eyes with ocular inflammatory disease.
Gangaputra S, Newcomb C, Armour R, Choi D, Ying GS, Groth S, Begum H, Fitzgerald T, Artornsombudh P, Daniel E, Bhatt N, Foster S, Jabs D, Levy-Clarke G, Nussenblatt R, Rosenbaum JT, Sen HN, Suhler E, Thorne J, Dreger K, Buchanich J, Kempen JH; Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Research Group. Gangaputra S, et al. Br J Ophthalmol. 2024 Feb 21;108(3):380-385. doi: 10.1136/bjo-2022-322236. Br J Ophthalmol. 2024. PMID: 36810151
Use of Immunosuppression and the Risk of Subsequent Overall or Cancer Mortality.
Kempen JH, Newcomb CW, Washington TL, Foster CS, Sobrin L, Thorne JE, Jabs DA, Suhler EB, Rosenbaum JT, Sen HN, Levy-Clarke GA, Nussenblatt RB, Bhatt NP, Lowder CY, Goldstein DA, Leiderman YI, Acharya NR, Holland GN, Read RW, Dunn JP, Dreger KA, Artornsombudh P, Begum HA, Fitzgerald TD, Kothari S, Payal AR, Daniel E, Gangaputra SS, Kaçmaz RO, Liesegang TL, Pujari SS, Khachatryan N, Maghsoudlou A, Suga HK, Pak CM, Helzlsouer KJ, Buchanich JM; Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study Research Group. Kempen JH, et al. Among authors: nussenblatt rb. Ophthalmology. 2023 Dec;130(12):1258-1268. doi: 10.1016/j.ophtha.2023.07.023. Epub 2023 Jul 26. Ophthalmology. 2023. PMID: 37499954
529 results